Changzhou No.4 pharmaceutical factory
Release date:



Changzhou No.4 Pharmaceutical Co., Ltd. is a national high-tech enterprise and one of the top 100 pharmaceutical companies in China. It is an innovative enterprise in Jiangsu Province, a green environmental protection enterprise in Jiangsu Province, and a top 10 five-star enterprise in Changzhou City. Won the National May 1st Labor award and the national harmonious labor relations enterprise; issued the corporate social responsibility report in Beijing and Shanghai for 9 consecutive years.

The company has 500 employees, with annual production capacity of DDS 3 billion preparations + 1.5 billion tablet capsules, 100 million sterile lyophilized and water needles, 50 million bottles of oral liquid, 50 million TTS transdermal patches and creams. Changzhou No.4 pharmaceutical adheres to innovation, development and steady operation, with sales of 2.6 billion yuan in 2018.

Changzhou No.4 Pharmaceutical Co., Ltd. is a national high-tech enterprise with a postdoctoral workstation. It has passed the three management system certification of national GMP, international environmental management ISO14001 and international occupational health and safety OHSMS 18001, and three products have passed the certification of FDA and CEP. In 2005, it was rated as a four-star star enterprise of Changzhou City, and ranked the top ten in technological innovation of Changzhou City.

The company has the first-class technology center and quality testing center in China. It has undertaken 5 national science and technology research projects and 863 plan, and has 21 independent process technology patents. It has won the national quality silver award and Provincial Quality Gold Award for many times. Oak? Series has been rated as famous brand products in Jiangsu Province for eight consecutive years.

The company has a raw material factory and preparation factory, with agile lean manufacturing and flexible production capacity. Current production capacity: 100 tons of 25 raw material intermediates, of which 50 tons are exported by the company; 20 million freeze-dried powder needles and 100 million water needles; 2 billion capsules, tablets, controlled and sustained-release preparations; 20 million frost and new transdermal patches.